Table 1

Subject characteristics*

Healthy subjectsStable CF patientsUnstable CF patients
Age, years14±0.715±0.915±0.7
Sex, F/M15/1614/1511/13
FEV1, % predicted110.4±2.586.6±2.975.7±3.4
FVC, % predicted113.0±2.289.1±3.186.1±4.8
BMI (kg/m2)20.3±0.520.1±0.619.3±0.7
CRP (mg/l)0.3±0.12.0±0.2
WBC (×109/l)8.2±0.410.6±0.6
Bacterial infection
Pseudomonas aeruginosa1615
Staphylococcus aureus76
S aureus + P aeruginosa3
Stenotrophomonas maltophilia1
S aureus + S maltophilia1
S aureus + P aeruginosa + S maltophilia1
Burkholderia cepacia1
CFTR genotype§
ICS (yes/no)23/624/0
Short-acting β2 agonists (yes/no)25/423/1
Inhaled tobramycin (yes/no)17/1217/7
Recombinant human DNase (yes/no)18/1122/2
  • Age range: healthy subjects: 9–23 years; stable CF patients: 9–24 years; unstable CF years: 9–23 years. Patients with CF with concomitant allergy and/or asthma were excluded from the study. No patient with CF, except one patient with stable CF, had pancreatic insufficiency. Full details of treatment are given in the online supplement.

  • * Data are expressed as n or mean±SEM. One-way ANOVA and unpaired t tests were used for comparing groups. Significance was defined as p<0.05.

  • Compared with healthy subjects.

  • Compared with patients with stable CF.

  • § Genotype was not determined in one patient with stable CF and in two patients with unstable CF.

  • BMI, body mass index; CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator; CRP, C reactive protein; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; ICS, inhaled corticosteroids; WBC, peripheral white blood cell counts.